Gao Chao-Qing, Zhou Jia-Jun, Tan Ya-Yin, Tong Chang-Jun
Hemopurification Center, Yijishan Hospital of Wannan Medical College, Wuhu, China.
Medicine (Baltimore). 2020 Nov 13;99(46):e23229. doi: 10.1097/MD.0000000000023229.
Uremic pruritus (UP) is a common and tormenting symptom in end-stage renal disease patients undergoing maintenance hemodialysis. An increasing number of studies have been published in recent years to support the effectiveness of montelukast for UP. We will conduct a comprehensive systematic review and meta-analysis to evaluate effectiveness of montelukast for UP in hemodialysis patients.
The following electronic databases were searched: Pubmed, Embase, Web of Science, Cochrane Library, the China National Knowledge Infrastructure, Chinese Biomedical Literature Database, and China Science and Technology Journal Database. The range of publication time was from the inception of the database to December 2020. Two reviewers will independently conduct article selection, data collection, and assessment of risk of bias. Any disagreement will be resolved by discussion with the third reviewer. Meta-analysis will be performed by Review Manager 5.3. The Cochrane Collaboration tool will be used to assess the risk of bias.
This study will provide a systematic synthesis of current published data to explore the effectiveness of montelukast for UP in hemodialysis patients.
This systematic review and meta-analysis will provide clinical evidence for the effectiveness of montelukast for UP in hemodialysis patients and inform our understanding of the value of montelukast in improving pruritus symptoms. This study will help clinicians, patients, and policy makers to make better decisions regarding the appropriate role of montelukast as a part of patient management routines.
INPLASY2020100043.
尿毒症瘙痒（UP）是维持性血液透析的终末期肾病患者常见且折磨人的症状。近年来发表了越来越多的研究来支持孟鲁司特治疗UP的有效性。我们将进行一项全面的系统评价和荟萃分析，以评估孟鲁司特对血液透析患者UP的有效性。
检索了以下电子数据库：PubMed、Embase、Web of Science、Cochrane图书馆、中国知网、中国生物医学文献数据库和中国科技期刊数据库。发表时间范围为数据库建立至2020年12月。两名评价者将独立进行文献筛选、数据收集和偏倚风险评估。任何分歧将通过与第三位评价者讨论解决。将使用Review Manager 5.3进行荟萃分析。将使用Cochrane协作工具评估偏倚风险。
本研究将对当前已发表的数据进行系统综合，以探讨孟鲁司特对血液透析患者UP的有效性。
这项系统评价和荟萃分析将为孟鲁司特对血液透析患者UP的有效性提供临床证据，并增进我们对孟鲁司特在改善瘙痒症状方面价值的理解。本研究将帮助临床医生、患者和政策制定者就是否将孟鲁司特作为患者管理常规的一部分做出更好的决策。
INPLASY2020100043。
